These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37439809)

  • 1. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
    Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
    Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
    Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
    J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
    McKay RR; Xie W; Ye H; Fennessy FM; Zhang Z; Lis R; Calagua C; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang PK; Wagner AA; Parsons JK; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
    J Urol; 2021 Jul; 206(1):80-87. PubMed ID: 33683939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
    McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
    Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
    Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
    McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
    J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
    Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
    Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
    Efstathiou E; Davis JW; Pisters L; Li W; Wen S; McMullin RP; Gormley M; Ricci D; Titus M; Hoang A; Zurita AJ; Tran N; Peng W; Kheoh T; Molina A; Troncoso P; Logothetis CJ
    Eur Urol; 2019 Oct; 76(4):418-424. PubMed ID: 31176622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
    Soloway MS; Sharifi R; Wajsman Z; McLeod D; Wood DP; Puras-Baez A
    J Urol; 1995 Aug; 154(2 Pt 1):424-8. PubMed ID: 7541859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Enzalutamide Prior to Prostatectomy.
    Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M; Novotny W; Wu K; Kantoff PW; Marck BT; Plymate S; Balk SP; Nelson PS; Matsumoto AM; Lis RT; Kibel A; Haas GP; Krivoshik A; Hannah A; Taplin ME
    Clin Cancer Res; 2017 May; 23(9):2169-2176. PubMed ID: 28151719
    [No Abstract]   [Full Text] [Related]  

  • 16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.